Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) Operating Expenses (2016 - 2025)

Plus Therapeutics has reported Operating Expenses over the past 15 years, most recently at $7.1 million for Q4 2025.

  • Quarterly Operating Expenses rose 33.83% to $7.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.5 million through Dec 2025, changed 0.04% year-over-year, with the annual reading at $20.5 million for FY2025, 0.04% changed from the prior year.
  • Operating Expenses was $7.1 million for Q4 2025 at Plus Therapeutics, up from $5.9 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $7.1 million in Q4 2025 and troughed at $2.5 million in Q1 2021.
  • The 5-year median for Operating Expenses is $5.0 million (2024), against an average of $4.6 million.
  • Year-over-year, Operating Expenses skyrocketed 150.64% in 2021 and then crashed 41.16% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $3.5 million in 2021, then soared by 63.56% to $5.7 million in 2022, then fell by 9.65% to $5.2 million in 2023, then grew by 2.73% to $5.3 million in 2024, then surged by 33.83% to $7.1 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Operating Expenses are $7.1 million (Q4 2025), $5.9 million (Q3 2025), and $2.9 million (Q2 2025).